Live Chat

BioNTech gráfico en tiempo real

instrument_fundamentals

Weekly Search
Weekly
Daily
Date Cerrar Change Cambio del % instr__open Alto Bajo

Markets.com news

bitcoin rising
Alec Malloy 2024 Aug 19, 16:05

Test News Spanish Article Only

BoE Acciones
French election results to drive European markets
markets.com Support Team 2024 Jul 04, 21:00

Adelanto semanal: Los resultados de las elecciones francesas clave para los mercados europeos

Forex Índices
Macron calls snap election, riles markets
markets.com Support Team 2024 Jun 29, 21:00

Adelanto semanal: ¿Francia desencadenará la próxima crisis del euro?

CPI
Businessman pointing hologram online banking icon.
markets.com Support Team 2024 Jun 20, 16:00

Adelanto semanal: Muchos datos e información sobre la inflación

Forex Índices

Información

Spread

0.9949

Spread (%)

0.8754 %

Apalancamiento

1:10

Interés a un día (Compra)

-0.0597 %

Interés a un día (Venta)

-0.0292 %

Divisa

USD

Horarios de los mercados

Market open

Martes

14:31 - 20:59

Lunes

14:31-20:59

Miércoles

14:31-20:59

Jueves

14:31-20:59

Viernes

14:31-20:59

instr__analysis_statistics

instr__open

---

instr__close

---

instr__52week_range

--- – ---

instr__market_cap

27212888064

instr__shares_outstand

239740000

instr__earnings_date

0000-00-00

Div Yield

2022-06-17

Ex-Dividend Date

2022-06-02

Forward annual dividend rate

0

Forward annual dividend yield

0

instr__eps

-2.01

instrument_learn_more

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

related_instruments

Activo
Vender
Comprar
Cambio del %
view_all_instruments
Trustpilot
Live Chat